EUVIMEDEUVIMED entdecken
Crossref

Side Effects of Low‐Dose Colchicine in Chronic Coronary Disease: A Post Hoc Analysis of the LoDoCo2 Trial

Jalina Jannink, Jenny van der Veen, Niekbachsh Mohammadnia, Marte F van der Bijl iD, Eric Boersma iD, Amber van Broekhoven iD, Charley A Budgeon iD, Jan H Cornel iD, John W Eikelboom iD, Saloua El Messaoudi iD, Stefan M Nidorf iD, Tjerk S J Opstal iD und 8 weitere

Journal of the American Heart Association · 12.11.2026

DOI: 10.1161/jaha.126.049844 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, online erschienen am 12.11.2026. Verfasst von Jalina Jannink und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Medicine University Medical Center Utrecht Utrecht The Netherlands. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Low‐dose colchicine reduces cardiovascular events in patients with chronic coronary disease. However, side effects may compromise compliance and lead to discontinuation of treatment. Therefore, we aimed to assess the incidence of side effects leading to discontinuation of treatment in the LoDoCo2 (Low‐Dose Colchicine 2) trial.

Methods

The LoDoCo2 trial was a randomized controlled trial evaluating colchicine versus placebo in patients with chronic coronary disease. Participants entered a 30‐day open‐label run‐in phase during which all participants received colchicine 0.5 mg once daily, followed by randomization to colchicine or placebo. Tolerability‐related side effects leading to treatment discontinuation were evaluated at the end of the 30‐day run‐in phase and during the randomized phase (median follow‐up, 29.5 [interquartile range, 21.6–47.4] months). Cumulative incidence of side effects was presented using Kaplan–Meier curves and compared by treatment arm using Cox proportional hazards models.

Results

During the 30‐day run‐in phase, 618 of 6519 (9.5%) participants reported side effects. Women had a higher risk of side effects than men during the 30‐day run‐in phase (odds ratio, 1.53 [95% CI, 1.23–1.89]). After randomization, 114 participants (4.2%) in the colchicine group and 120 (4.4%) in the placebo group discontinued treatment due to side effects (hazard ratio [HR], 0.95 [95% CI, 0.73–1.22]). Gastrointestinal symptoms were most common (colchicine 2.0% versus placebo 1.7%) followed by myalgia (colchicine 1.2% versus placebo 1.6%). No differences in the risk of side effects between colchicine and placebo were seen for any of the subgroups. Women did have a higher risk of reporting side effects compared with men, regardless of assigned treatment (HR, 1.66 [95% CI, 1.22–2.25]).

Conclusions

In patients with chronic coronary disease that tolerated initial treatment with low‐dose colchicine, long‐term discontinuation due to side effects was uncommon and did not differ between colchicine and placebo. Registration URL: https://www.anzctr.org/au ; Unique identifier: ACTRN12614000093684.

Schlagwörter

Stichwörter der Autor:innen

chronic coronary artery diseaselow‐dose colchicineside effects

Autor:innen und Institutionen

  • Department of Vascular Medicine University Medical Center Utrecht Utrecht The Netherlands.
  • Department of Cardiology Meander Medical Center Amersfoort The Netherlands.
  • Faculty of Medicine University Medical Center Utrecht Utrecht The Netherlands.
  • Department of Cardiology Radboud University Medical Center Nijmegen The Netherlands.
  • Department of Internal Medicine Erasmus Medical Center Rotterdam The Netherlands.
  • Department of Cardiology Erasmus Medical Center Rotterdam The Netherlands.

ORCID-Profile: Marte F van der Bijl, Eric Boersma, Amber van Broekhoven, Charley A Budgeon, Jan H Cornel, John W Eikelboom, Saloua El Messaoudi, Stefan M Nidorf, Tjerk S J Opstal, Jeanine E Roeters van Lennep, Hester M den Ruijter, Astrid Schut, Jan Tijssen, Fabrice M A C Martens, Frank L J Visseren, Arend Mosterd, Aernoud T L Fiolet

Zitieren

APA

Jannink, J., van der Veen, J., Mohammadnia, N., van der Bijl, M. F., Boersma, E., van Broekhoven, A., Budgeon, C. A., Cornel, J. H., Eikelboom, J. W., El Messaoudi, S., Nidorf, S. M., Opstal, T. S. J., Roeters van Lennep, J. E., den Ruijter, H. M., Schut, A., Tijssen, J., Martens, F. M. A. C., Visseren, F. L. J., Mosterd, A., & Fiolet, A. T. L. (2026). Side Effects of Low‐Dose Colchicine in Chronic Coronary Disease: A Post Hoc Analysis of the LoDoCo2 Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.126.049844

Vancouver

Jannink J, van der Veen J, Mohammadnia N, van der Bijl MF, Boersma E, van Broekhoven A, et al. Side Effects of Low‐Dose Colchicine in Chronic Coronary Disease: A Post Hoc Analysis of the LoDoCo2 Trial. Journal of the American Heart Association. 2026. doi:10.1161/jaha.126.049844

BibTeX
@article{Jannink2026,
  author = {Jannink, Jalina and van der Veen, Jenny and Mohammadnia, Niekbachsh and van der Bijl, Marte F and Boersma, Eric and van Broekhoven, Amber and Budgeon, Charley A and Cornel, Jan H and Eikelboom, John W and El Messaoudi, Saloua and Nidorf, Stefan M and Opstal, Tjerk S J and Roeters van Lennep, Jeanine E and den Ruijter, Hester M and Schut, Astrid and Tijssen, Jan and Martens, Fabrice M A C and Visseren, Frank L J and Mosterd, Arend and Fiolet, Aernoud T L},
  title = {Side Effects of Low‐Dose Colchicine in Chronic Coronary Disease: A Post Hoc Analysis of the LoDoCo2 Trial},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.126.049844}
}
Kostenlos starten →